Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011) using ...

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

1 Department of Anatomy, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia 2 Department of Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia Introduction: ...

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by Fretz et al., ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March 4 in JAMA ...

A large-scale study analyzing data from over 60 million patients finds no evidence that GLP-1 receptor agonists increase suicidality risk in type 2 diabetes patients, challenging previous safety ...